Oppenheimer expects Vaccinex’s VX15 anti-SEMA4D antibody to rout treatment resistance in advanced solid tumors and delay the progress of Huntington’s disease. A Phase 2 trial in the latter indication has demonstrated statistically significant slowdowns in cursory reads.
“Should this signal continue to be borne out in longer-term evaluation, VX15 may represent a leap forward for a treatment paradigm that currently offers only symptomatic therapies of narrow scope,” Gershell said in a Tuesday note. (See the analyst's track record here.)
The candidate’s “clean” safety profile and boost to widely used checkpoint inhibitors, coupled with Vaccinex’s expertise in SEMA4D, are seen to help the firm break into the market of challenging conditions. Evidence is expected to arrive in the form of mid-2019 data for non-small cell lung cancer and late-2020 reports for Huntington’s disease.
“Although key clinical readouts lie one to two years away, we believe VCNX shares will reward the patient investor,” Gershell said.
At the same time, the firm’s ActivMAb platform is seen to “streamline novel therapeutic development” in indications including multiple sclerosis.
Vaccinex shares were trading up 2.87 percent to $10.28 at the time of publication Tuesday.
Chardan: Tocagen's Brain, Spinal Cord Tumor Candidate Has 7M Potential
Why Raymond James Is Bullish On Deciphera, Dova Pharmaceuticals
Latest Ratings for VCNX
|Sep 2018||Oppenheimer||Initiates Coverage On||Outperform|
View More Analyst Ratings for VCNX
View the Latest Analyst Ratings
See more from Benzinga
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.